- Arthritis, encompassing conditions such as osteoarthritis, rheumatoid arthritis, and psoriatic arthritis, continues to pose a major public health burden in the U.S., with increasing patient volumes driving demand for advanced and personalized treatment solutions across both clinical and outpatient settings due to chronic pain, disability, and reduced quality of life
- The rising prevalence of arthritis is primarily driven by an aging population, increasing obesity rates, sedentary lifestyles, and improved awareness and diagnosis of joint-related disorders
- In 2024, the U.S. arthritis market was characterized by strong growth in biologics and targeted therapies, supported by a well-established healthcare infrastructure, high treatment accessibility, and continued innovation from pharmaceutical and biotechnology companies
- Demand for advanced options such as JAK inhibitors, biosimilars, and minimally invasive procedures is accelerating, particularly as patients and physicians seek longer-lasting, more effective interventions
- The osteoarthritis segment held the largest share of the U.S. arthritis market at 52.1% in 2024, propelled by its widespread prevalence in the aging population and growing emphasis on early intervention, lifestyle modification, and regenerative treatment approaches
